Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial

Patrick Loehrer, D. Johnson, P. Elson, Lawrence Einhorn, D. Trump

Research output: Contribution to journalArticle

205 Citations (Scopus)

Abstract

Purpose: This prospective, randomized trial was designed to determine if three cycles of cisplatin plus etoposide (PVP16) can produce therapeutic results comparable to three cycles of cisplatin, etoposide, and bleomycin (PVP16B) in patients with disseminated germ cell tumors. Patients and Methods: One hundred seventy-eight patients with minimal- or moderate-stage disease (Indiana staging system) were randomized to receive cisplatin (20 mg/m2 on days 1 to 5) plus etoposide (100 mg/m2 on days 1 to 5) with or without weekly bleomycin (30 IU/wk for 9 consecutive weeks). Following three cycles of chemotherapy over 9 weeks, patients with residual radiographic disease underwent surgical resection. If persistent carcinoma was noted, two additional 3-week courses of chemotherapy were administered. Results: One hundred seventy-one patients were fully assessable for response and survival. The two treatment groups were similar with respect to patient characteristics. The toxicities were comparable between the two arms. No clinically significant incidence of pulmonary toxicity occurred with PVP16B. Overall, 81 of 86 patients (94%) who received PVP16B and 75 of 85 patients (88%) who received PVP16 achieved a disease-free status with chemotherapy and/or surgery. However, greater numbers of treatment failures, including persistent carcinoma in postchemotherapy resected residual disease and relapses from complete remission, occurred on the arm without bleomycin (overall adverse outcome, P = .004). The failure-free (86% v 69%; P = .01) and overall survival (95% v 86%; P = .01) rates were inferior on the PVP16 arm. Conclusion: Bleomycin is an essential component of PVP16B therapy in patients who receive three cycles of treatment for minimal- or moderate- stage disseminated germ cell tumors.

Original languageEnglish
Pages (from-to)470-476
Number of pages7
JournalJournal of Clinical Oncology
Volume13
Issue number2
StatePublished - 1995

Fingerprint

Germ Cell and Embryonal Neoplasms
Bleomycin
Etoposide
Cisplatin
Drug Therapy
Carcinoma
indium-bleomycin
Survival
Therapeutics
Treatment Failure
Recurrence
Lung
Incidence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Importance of bleomycin in favorable-prognosis disseminated germ cell tumors : An Eastern Cooperative Oncology Group trial. / Loehrer, Patrick; Johnson, D.; Elson, P.; Einhorn, Lawrence; Trump, D.

In: Journal of Clinical Oncology, Vol. 13, No. 2, 1995, p. 470-476.

Research output: Contribution to journalArticle

@article{84f94421fe0b4693b1bfee8fa7063111,
title = "Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial",
abstract = "Purpose: This prospective, randomized trial was designed to determine if three cycles of cisplatin plus etoposide (PVP16) can produce therapeutic results comparable to three cycles of cisplatin, etoposide, and bleomycin (PVP16B) in patients with disseminated germ cell tumors. Patients and Methods: One hundred seventy-eight patients with minimal- or moderate-stage disease (Indiana staging system) were randomized to receive cisplatin (20 mg/m2 on days 1 to 5) plus etoposide (100 mg/m2 on days 1 to 5) with or without weekly bleomycin (30 IU/wk for 9 consecutive weeks). Following three cycles of chemotherapy over 9 weeks, patients with residual radiographic disease underwent surgical resection. If persistent carcinoma was noted, two additional 3-week courses of chemotherapy were administered. Results: One hundred seventy-one patients were fully assessable for response and survival. The two treatment groups were similar with respect to patient characteristics. The toxicities were comparable between the two arms. No clinically significant incidence of pulmonary toxicity occurred with PVP16B. Overall, 81 of 86 patients (94{\%}) who received PVP16B and 75 of 85 patients (88{\%}) who received PVP16 achieved a disease-free status with chemotherapy and/or surgery. However, greater numbers of treatment failures, including persistent carcinoma in postchemotherapy resected residual disease and relapses from complete remission, occurred on the arm without bleomycin (overall adverse outcome, P = .004). The failure-free (86{\%} v 69{\%}; P = .01) and overall survival (95{\%} v 86{\%}; P = .01) rates were inferior on the PVP16 arm. Conclusion: Bleomycin is an essential component of PVP16B therapy in patients who receive three cycles of treatment for minimal- or moderate- stage disseminated germ cell tumors.",
author = "Patrick Loehrer and D. Johnson and P. Elson and Lawrence Einhorn and D. Trump",
year = "1995",
language = "English",
volume = "13",
pages = "470--476",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "2",

}

TY - JOUR

T1 - Importance of bleomycin in favorable-prognosis disseminated germ cell tumors

T2 - An Eastern Cooperative Oncology Group trial

AU - Loehrer, Patrick

AU - Johnson, D.

AU - Elson, P.

AU - Einhorn, Lawrence

AU - Trump, D.

PY - 1995

Y1 - 1995

N2 - Purpose: This prospective, randomized trial was designed to determine if three cycles of cisplatin plus etoposide (PVP16) can produce therapeutic results comparable to three cycles of cisplatin, etoposide, and bleomycin (PVP16B) in patients with disseminated germ cell tumors. Patients and Methods: One hundred seventy-eight patients with minimal- or moderate-stage disease (Indiana staging system) were randomized to receive cisplatin (20 mg/m2 on days 1 to 5) plus etoposide (100 mg/m2 on days 1 to 5) with or without weekly bleomycin (30 IU/wk for 9 consecutive weeks). Following three cycles of chemotherapy over 9 weeks, patients with residual radiographic disease underwent surgical resection. If persistent carcinoma was noted, two additional 3-week courses of chemotherapy were administered. Results: One hundred seventy-one patients were fully assessable for response and survival. The two treatment groups were similar with respect to patient characteristics. The toxicities were comparable between the two arms. No clinically significant incidence of pulmonary toxicity occurred with PVP16B. Overall, 81 of 86 patients (94%) who received PVP16B and 75 of 85 patients (88%) who received PVP16 achieved a disease-free status with chemotherapy and/or surgery. However, greater numbers of treatment failures, including persistent carcinoma in postchemotherapy resected residual disease and relapses from complete remission, occurred on the arm without bleomycin (overall adverse outcome, P = .004). The failure-free (86% v 69%; P = .01) and overall survival (95% v 86%; P = .01) rates were inferior on the PVP16 arm. Conclusion: Bleomycin is an essential component of PVP16B therapy in patients who receive three cycles of treatment for minimal- or moderate- stage disseminated germ cell tumors.

AB - Purpose: This prospective, randomized trial was designed to determine if three cycles of cisplatin plus etoposide (PVP16) can produce therapeutic results comparable to three cycles of cisplatin, etoposide, and bleomycin (PVP16B) in patients with disseminated germ cell tumors. Patients and Methods: One hundred seventy-eight patients with minimal- or moderate-stage disease (Indiana staging system) were randomized to receive cisplatin (20 mg/m2 on days 1 to 5) plus etoposide (100 mg/m2 on days 1 to 5) with or without weekly bleomycin (30 IU/wk for 9 consecutive weeks). Following three cycles of chemotherapy over 9 weeks, patients with residual radiographic disease underwent surgical resection. If persistent carcinoma was noted, two additional 3-week courses of chemotherapy were administered. Results: One hundred seventy-one patients were fully assessable for response and survival. The two treatment groups were similar with respect to patient characteristics. The toxicities were comparable between the two arms. No clinically significant incidence of pulmonary toxicity occurred with PVP16B. Overall, 81 of 86 patients (94%) who received PVP16B and 75 of 85 patients (88%) who received PVP16 achieved a disease-free status with chemotherapy and/or surgery. However, greater numbers of treatment failures, including persistent carcinoma in postchemotherapy resected residual disease and relapses from complete remission, occurred on the arm without bleomycin (overall adverse outcome, P = .004). The failure-free (86% v 69%; P = .01) and overall survival (95% v 86%; P = .01) rates were inferior on the PVP16 arm. Conclusion: Bleomycin is an essential component of PVP16B therapy in patients who receive three cycles of treatment for minimal- or moderate- stage disseminated germ cell tumors.

UR - http://www.scopus.com/inward/record.url?scp=0028860147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028860147&partnerID=8YFLogxK

M3 - Article

C2 - 7531223

AN - SCOPUS:0028860147

VL - 13

SP - 470

EP - 476

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 2

ER -